Syros Pharmaceuticals Inc (0S90.DU)
Dusseldorf - Dusseldorf Delayed price. Currency in EUR
Add to watchlist
As of 08:11AM CEST. Market open.
| Previous close | 4.9000 |
| Open | 4.8800 |
| Bid | 4.9400 x N/A |
| Ask | 5.2500 x N/A |
| Day's range | 4.8600 - 4.9000 |
| 52-week range | 1.9500 - 7.1600 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksAnalysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for
Syros Pharmaceuticals (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksThe Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.
ZacksSyros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML
The FDA bestows a Fast Track Designation to Syros' (SYRS) pipeline candidate, tamibarotene, in combination with venetoclax and azacitidine to treat newly diagnosed acute myeloid leukemia. Stock rises.
© 2024 Yahoo. All rights reserved.